High-throughput, GMP-aligned automation solutions engineered for precision drug elution, continuous cell cultivation, aerosol exposure, and microbiological safety.
How North American life science ecosystems are transitioning from manual benchtop incubation to AI-assisted, closed-loop cell cultivation platforms.
The United States remains the global epicentre of biotechnology innovation, anchored by premier biotech clusters in Massachusetts (Boston-Cambridge), the San Francisco Bay Area, San Diego, the North Carolina Research Triangle (RTP), Philadelphia, and the Texas Medical Center in Houston. In these highly competitive hubs, the race to develop novel monoclonal antibodies (mAbs), mRNA vaccines, recombinant proteins, and autologous/allogeneic cell therapies (such as CAR-T and TCR therapies) has pushed traditional manual cell culture to its physical and operational limits.
Manual pipetting and flask inspection introduce human error, inter-batch variability, and substantial contamination risks—factors that directly jeopardize FDA cGMP and GLP validation. Automated cell culture machines have evolved from high-throughput screening accessories into non-negotiable infrastructure, enabling 24/7 autonomous monitoring of confluence, nutrient exchange, dissolved oxygen (DO), pH, and cell viability.
Unlike traditional biologics that scale up into massive thousand-liter vats, personalized cell therapies require automated "scale-out" parallel processing. Automated machines maintain hundreds of independent micro-environments simultaneously without cross-contamination.
Modern U.S. research facilities demand machine vision and deep-learning algorithms capable of calculating cell confluence, morphology transitions, and apoptosis rates in real time without sacrificing cultures or breaking sterile containment.
Regulatory compliance requires exhaustive electronic batch records (EBR), audit trails, and strict parameter control. Turnkey automation eliminates subjective human charting and provides immutable digital traceability for every culture cycle.
Beijing Huironghe Technology Co., Ltd. (Overseas Brand "HRHINS") – A Global Pioneer in Scientific Instrumentation & Automated Bio-Systems.
Founded in 2010 with a registered capital of 10 million yuan, Beijing Huironghe Technology Co., Ltd. (overseas brand "HRHINS") is headquartered in the prestigious Beijing Economic-Technological Development Area. As a global manufacturing partner serving laboratories across North America, Europe, and Asia, HRHINS specializes in the complete R&D lifecycle, precision manufacturing, worldwide distribution, and lifecycle technical services for inhalation toxicity, genetic toxicity, inhaler characterization, aerosol measurement, and custom laboratory automation systems.
Recognized as a National High-tech Enterprise and a designated Beijing Municipal Corporate Science and Technology R&D Institution, HRHINS holds national honors including Beijing "Specialized, Refined, Unique, and Innovative" SME status, China Manufacturing Champion Enterprise accreditation, and the Beijing Intellectual Property Demonstration Enterprise award. In 2022, HRHINS was honored as a National "Little Giant" SME—the first in the aerosol scientific instrument discipline—and earned the prestigious Second Prize in Scientific and Technological Progress from the Tianjin Municipal Government.
Crucially, all HRHINS products—from complex aerosol generation and optical particle detection to automated cell culture, multi-axis liquid handling, and centralized software system control—are based on independent intellectual property. Our comprehensive aerosol and cell exposure suites support studies across standard mammalian models as well as advanced in vitro cell culture exposures at the Air-Liquid Interface (ALI).
These mission-critical solutions are widely utilized by U.S. and international GLP laboratories, industrial toxicology centers, academic research institutes, biopharma contract development and manufacturing organizations (CDMOs), and hospital pulmonary research divisions.
Occupying over 3,000 sqm of modern R&D centers, cleanroom assembly bays, and precision validation suites to deliver uncompromised quality.
HRHINS operates under strict international benchmarks, holding certifications for the ISO 9001:2015 Quality Management System, ISO 14001:2015 Environmental Management System, ISO 45001:2018 Occupational Health and Safety Management System, and GB/T 29490-2013 Intellectual Property Management System.
In 2018, HRHINS supported the establishment of the Respiratory Toxicology Committee of the Chinese Society of Toxicology and became its founding sponsor. The company maintains executive council memberships across the Chinese Society of Toxicology, the Chinese Environmental Mutagen Society, and the Zhongguancun New Bio-pharmaceutical Industry Alliance.
| System Dimension | Traditional Manual Cell Culture | HRHINS Automated Bioprocess Architecture | U.S. Laboratory Benefit |
|---|---|---|---|
| Sterility & Contamination | Open BSC operation; vulnerable to human handling vectors. | HEPA-filtered Class A enclosed chamber with UV-C decontamination. | 99.9% reduction in biological contamination & batch abandonment. |
| Media Dosing Precision | Manual pipetting with ±5-10% volumetric drift over shifts. | Micro-peristaltic & robotic syringe fluidics ( | Unsurpassed reproducibility for cellular kinetics & metabolomics. |
| Exposure Compatibility | Submerged monolayer cultures only; non-physiological. | Air-Liquid Interface (ALI) direct aerosol & nanoparticle exposure. | Accurate predictive models for pulmonary drug & inhalation toxicology. |
| Data Integrity & Audit | Paper lab notebooks, manual camera captures, disparate files. | Centralized PLC/PC control with encrypted 21 CFR Part 11 audit trails. | Seamless IND/NDA filing support with automated data verification. |
Engineered to solve real-world bottleneck challenges across regenerative medicine, contract testing, inhalation therapeutics, and agricultural biosafety.
Designed to interface directly with our aerosol exposure chambers and cascade impactors. Enables primary human bronchial epithelial cells (HBEC) to be cultured at the air-liquid interface and exposed to calibrated concentrations of aerosols, environmental pollutants, or dry-powder inhalers (DPIs).
Coupled with our Fully Automated Ames Test System, laboratories can automate the tedious fluctuation assay steps, bacterial incubation, and colorimetric reading for mutagenic screening, boosting sample volume fivefold while drastically reducing labor overhead.
Integrates automated solid-phase extraction, matrix dispersion, and colony monitoring for high-throughput food microbiology screening compliant with USDA, AOAC, and FDA BAM protocols for multi-residue pesticide and pathogen detection.
Browse our complete catalog of precision instruments, sample preparation shakers, cell exposure devices, and automated analytical platforms available for delivery across the United States.
Comprehensive lifecycle engineering support, FAT/SAT validation protocols, and rapid parts delivery for our North American partners.
Every automated instrument from HRHINS is backed by deep application engineering support. Whether you require custom adapter manifolds for multi-well plates, specialized Air-Liquid Interface (ALI) cell exposure chambers, or integration into automated robotic transport tracks (such as SCARA or collaborative 6-axis arms), our Beijing R&D center collaborates directly with your technical team.
We provide full Factory Acceptance Testing (FAT), Site Acceptance Testing (SAT), and comprehensive Installation Qualification/Operational Qualification (IQ/OQ/PQ) documentation packages to ensure that your automated cell culture and testing workstations achieve regulatory compliance on day one.
With an established logistics network serving clients across California, Massachusetts, New Jersey, North Carolina, Texas, and Washington, HRHINS guarantees timely delivery of consumables, precision spare parts, and calibration modules. Our remote diagnostic telemetry allows our senior software and hardware engineers to support your facility with zero delay, ensuring maximum operational uptime for high-stakes biopharma campaigns.